Tag:
Tracleer
Latest Headlines
Latest Headlines
Actelion surges as positive PhIII macitentan data reignites buyout buzz
The data signals to investors that the Swiss company can be ready for the loss of patent protection on its primary earner with the introduction of another blockbuster.
Actelion hunts for answers about 120 deaths in key drug trial
Actelion ( $ATLN ) CEO Jean-Paul Clozel has been clear about the importance of macitentan for the Swiss biotech's future in the blockbuster market for pulmonary arterial hypertension (PAH) drugs. So
Analysts give Actelion's key lung drug 63% odds of success
Swiss biotech Actelion ( $ATLN ) could use a win for its experimental lung drug. In need for a new product to follow its big hit Tracleer, the company's big moment for its lung disease treatment
Actelion braces for looming pivotal data on blockbuster macitentan program
Actelion's ( $ATLN ) approach to the year ahead might best be described as hoping for the best while preparing for the worst. Crucial late-stage data on macitentan is due to read out in the second
